SEP 21, 2020 12:41 PM PDT

The Protein ETV1 May Act as a Biomarker for Gastrointestinal Cancer

WRITTEN BY: Jasper Cantrell

Cancer is an incredibly diverse disease. It has many types and even sub-types, with a vast range of characteristics. Some cancers even have complex genetic mutations, while others have a single defining mutation.

Gastrointestinal stromal tumors (GISTs) are an example of a cancer with one consistent mutation. In this case, it is a “gain of function” mutation that causes the c-kit signaling pathway to be constantly in the “on” state. The critical protein in this pathway is the receptor tyrosine kinase KIT, which is normally activated by stem cell factor and plays a role in cell survival and proliferation. These kinases are critical players in cancer as well, as their aberrant activation is common in many types.

Another protein, the transcription factor ETV1, was also found to play a role in tumorigenesis alongside KIT in gastrointestinal stromal tumors. Conflicting evidence suggested that ETV1 might be a promising biomarker for the prognosis of gastrointestinal stromal tumors. A team out of Nagoya University wanted to examine the relationship between KIT and ETV1 and determine if ETV1 expression had any prognostic value.

To do this, the team gathered data from 64 gastrointestinal stromal tumor patients. All but four of these had mutations affecting the c-kit pathway. Eleven patients suffered from recurrence, which the team classified as aggressive subtyping.  

The team found that ETV1 was expressed at higher levels in gastrointestinal stromal tumors than in other cancers. The team classified the 64 patients from low to high risk and then examined the ETV1 levels in each. High expression was more likely to be found in low-risk patients, with aggressive tumors showing much lower ETV1 levels. Further analysis showed that high ETV1 levels corresponded to a better recurrence-free survival compared to low ETV1, with there being no difference in the overall survival rate.

Although the dataset’s size was small, this study supports the idea that ETV1 is expressed in gastrointestinal stromal tumors at relatively high levels. It also shows that it may act as a prognostic indicator for patients, with high ETV1 levels signaling a better recurrence-free survival. Another study with a larger sample size will be needed to confirm this observation. Still, this evidence helps further understand gastrointestinal stromal tumors and how we might best fight them.

The study concludes, “low ETV1 expression was associated with worse RFS and was revealed as an independent factor of recurrence in addition to conventional factors. ETV1 expression could be a predictor of aggressive malignant GISTs. An evaluation system based on ETV1 expression may help choose patients who need adjuvant chemotherapy.”

Sources: Nature Scientific Reports, ImedexCME

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
APR 06, 2021
Immunology
Lymphoma Patient Cured by "Reeducating" their Immune System
APR 06, 2021
Lymphoma Patient Cured by "Reeducating" their Immune System
Australian researchers have used a breakthrough therapy to cure a patient diagnosed with a rare brain lymphoma, a form o ...
APR 25, 2021
Genetics & Genomics
How Did the Chernobyl Disaster Affect Human Health?
APR 25, 2021
How Did the Chernobyl Disaster Affect Human Health?
It's been about 35 years since the disaster at the Chernobyl nuclear power plant. Now researchers have investigated whet ...
MAY 13, 2021
Genetics & Genomics
Explore Ways to Enhance Biomarker Discovery Research
MAY 13, 2021
Explore Ways to Enhance Biomarker Discovery Research
Enhance your existing research or discover new methods with a suite of NGS tools and techniques to find and characterize ...
JUN 06, 2021
Cancer
New drug reduces tumor size in lung cancer patients with KRAS gene mutation
JUN 06, 2021
New drug reduces tumor size in lung cancer patients with KRAS gene mutation
The most recent results from the CODEBREAK 100 phase 2 clinical trial support the use of the drug sotorasib to reduce tu ...
JUN 29, 2021
Cancer
Heart Failure Linked to Increased Cancer Risk
JUN 29, 2021
Heart Failure Linked to Increased Cancer Risk
A study by researchers in Germany suggests that patients with heart failure are more likely to develop cancer than those ...
JUL 07, 2021
Cancer
Chemotherapy Disrupts Gut Bacteria in Cancer Patients
JUL 07, 2021
Chemotherapy Disrupts Gut Bacteria in Cancer Patients
Researchers from Australia have found that the conventional chemotherapy used to treat various cancers disrupts the comp ...
Loading Comments...